Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Pembrolizumab works better than chemotherapy alone as initial treatment for NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 2405
Rating:

Dr Gilberto Lopes - Sylvester Comprehensive Cancer Center, Miami, USA

Dr Lopes speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from a trial that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements.

For more on these results, watch Dr Lopes present the data in a press conference here and read news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

Related videos

follow us

Breast cancer epidemiology video


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation